AACR 2017: Combination HER2-targeted therapy effective in heavily pretreated HER2 positive colorectal cancer patients

A combination of two HER2-targeted therapies, trastuzumab and lapatinib, showed clinical benefit in patients with heavily pretreated HER2-positive metastatic colorectal cancer, according to final results from the phase II clinical trial HERACLES,...

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2nZsSfp
via IFTTT